Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Braz. j. infect. dis ; 22(1): 30-36, Jan.-feb. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-951621

RESUMO

ABSTRACT The in vitro susceptibility of 105 clinical and environmental strains of Aspergillus fumigatus and Aspergillus flavus to antifungal drugs, such as amphotericin B, azoles, and echinocandins was evaluated by the broth microdilution method proposed by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Following the EUCAST-proposed breakpoints, 20% and 25% of the clinical and environmental isolates of A. fumigatus, respectively, were found to be resistant to itraconazole (Minimal Inhibitory Concentration, MIC > 2.0 mg/L). Voriconazole showed good activity against A. fumigatus and A. flavus strains, except for one clinical strain of A. fumigatus whose MIC was 4.0 mg/L. Posaconazole (≤0.25 mg/L) also showed appreciable activity against both species of Aspergillus, except for six A. fumigatus strains with relatively higher MICs (0.5 mg/L). The MICs for Amphotericin B ranged from 0.06 to 1.0 mg/L for A. fumigatus, but were much higher (0.5-8.0 mg/L) for A. flavus. Among the echinocandins, caspofungin showed a geometric mean of 0.078 and 0.113 against the clinical and environmental strains of A. flavus, respectively, but had elevated minimal effective concentrations (MECs) for seven of the A. fumigatus strains. Anidulafungin and micafungin exhibited considerable activity against both A. fumigatus and A. flavus isolates, except for one environmental isolate of A. fumigatus that showed an MEC of 1 mg/L to micafungin. Our study proposes that a detailed investigation of the antifungal susceptibility of the genus Aspergillus from different regions of Brazil is necessary for establishing a response profile against the different classes of antifungal agents used in the treatment of aspergillosis.


Assuntos
Humanos , Aspergillus flavus/efeitos dos fármacos , Aspergillus fumigatus/efeitos dos fármacos , Antifúngicos/farmacologia , Aspergillus flavus/isolamento & purificação , Aspergillus fumigatus/isolamento & purificação , Valores de Referência , Brasil , Testes de Sensibilidade Microbiana , Reação em Cadeia da Polimerase , Farmacorresistência Fúngica Múltipla
2.
Braz J Infect Dis ; 22(1): 30-36, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29172033

RESUMO

The in vitro susceptibility of 105 clinical and environmental strains of Aspergillus fumigatus and Aspergillus flavus to antifungal drugs, such as amphotericin B, azoles, and echinocandins was evaluated by the broth microdilution method proposed by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Following the EUCAST-proposed breakpoints, 20% and 25% of the clinical and environmental isolates of A. fumigatus, respectively, were found to be resistant to itraconazole (Minimal Inhibitory Concentration, MIC>2.0mg/L). Voriconazole showed good activity against A. fumigatus and A. flavus strains, except for one clinical strain of A. fumigatus whose MIC was 4.0mg/L. Posaconazole (≤0.25mg/L) also showed appreciable activity against both species of Aspergillus, except for six A. fumigatus strains with relatively higher MICs (0.5mg/L). The MICs for Amphotericin B ranged from 0.06 to 1.0mg/L for A. fumigatus, but were much higher (0.5-8.0mg/L) for A. flavus. Among the echinocandins, caspofungin showed a geometric mean of 0.078 and 0.113 against the clinical and environmental strains of A. flavus, respectively, but had elevated minimal effective concentrations (MECs) for seven of the A. fumigatus strains. Anidulafungin and micafungin exhibited considerable activity against both A. fumigatus and A. flavus isolates, except for one environmental isolate of A. fumigatus that showed an MEC of 1mg/L to micafungin. Our study proposes that a detailed investigation of the antifungal susceptibility of the genus Aspergillus from different regions of Brazil is necessary for establishing a response profile against the different classes of antifungal agents used in the treatment of aspergillosis.


Assuntos
Antifúngicos/farmacologia , Aspergillus flavus/efeitos dos fármacos , Aspergillus fumigatus/efeitos dos fármacos , Aspergillus flavus/isolamento & purificação , Aspergillus fumigatus/isolamento & purificação , Brasil , Farmacorresistência Fúngica Múltipla , Humanos , Testes de Sensibilidade Microbiana , Reação em Cadeia da Polimerase , Valores de Referência
3.
Rev Iberoam Micol ; 25(3): 176-8, 2008 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-18785789

RESUMO

Invasive pulmonary aspergillosis is typically caused by a single Aspergillus species, most frequently Aspergillus fumigatus. Here we report that a lung transplant recipient developed invasive aspergillosis due to a mixed infection caused by Aspergillus flavus and A. fumigatus. The implications for this unusual finding are discussed.


Assuntos
Aspergillus flavus , Aspergillus fumigatus , Aspergilose Pulmonar Invasiva/microbiologia , Adulto , Evolução Fatal , Humanos , Masculino
4.
Rev Iberoam Micol ; 21(3): 143-6, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15709789

RESUMO

Clinical protocols of 28 cases of cryptococcemia studied between April 1995 and November 2002 were reviewed. The varieties of Cryptococcus neorformans, the underlying disease, and the severity and outcome of the disease were emphasized. Most patients were immunossupressed (89.3% with AIDS) and Cryptococcus neoformans var. grubii was the main recovered variety (92.8%). Regardless of antifungal treatment, in-hospital mortality was 41% strongly associated with APACHE II score, >14 (p<0.01).


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/epidemiologia , Criptococose/epidemiologia , Fungemia/epidemiologia , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Infecções Oportunistas Relacionadas com a AIDS/mortalidade , APACHE , Adolescente , Adulto , Antifúngicos/uso terapêutico , Argentina/epidemiologia , Contagem de Linfócito CD4 , Criança , Criptococose/tratamento farmacológico , Criptococose/etiologia , Criptococose/mortalidade , Suscetibilidade a Doenças , Feminino , Fungemia/tratamento farmacológico , Fungemia/etiologia , Fungemia/mortalidade , Mortalidade Hospitalar , Humanos , Cirrose Hepática/complicações , Transplante de Pulmão , Masculino , Meningite Criptocócica/tratamento farmacológico , Meningite Criptocócica/etiologia , Meningite Criptocócica/mortalidade , Pessoa de Meia-Idade , Complicações Pós-Operatórias/microbiologia , Estudos Retrospectivos , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA